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N-acetylcysteine attenuates the progression of chronic renal
failure.
Background. Lipid peroxidation impairs renal function. Al-
dosterone contributes to renal injury in the remnant kidney
model. This study aimed to determine the effects of the antioxi-
dant N-acetylcysteine (NAC) on renal function and aldosterone
levels in chronic renal failure.
Methods. Adult male Wistar rats were submitted to 5/6
nephrectomy or laparotomy (sham-operated) and received
NAC (600 mg/L in drinking water, initiated on postoperative
day 7 or 60), spironolactone (1.5 g/kg of diet initiated on post-
operative day 7), the NAC-spironolactone combination or no
treatment. Clearance studies were performed on postoperative
days 21, 60, and 120.
Results. Mean daily NAC and spironolactone ingestion was
comparable among the treated groups. Mean weight gain was
higher in NAC-treated rats than in untreated rats. A signifi-
cant decrease in urinary thiobarbituric acid reactive substances
(TBARS) concentrations, a lipid peroxidation marker, was ob-
served in NAC-treated rats. By day 120, glomerular filtration
rate (GFR), which dropped dramatically in untreated rats,
was stable (albeit below normal) in NAC-treated rats, which
also presented lower proteinuria, glomerulosclerosis index, and
blood pressure, together with attenuated cardiac and adrenal
hypertrophy. These beneficial effects, observed even when NAC
was initiated on postnephrectomy day 60, were accompanied
by a significant reduction in plasma aldosterone and urinary
sodium/potassium ratio. The NAC-spironolactone combination
lowered blood pressure and improved GFR protection.
Conclusion. The NAC-spironolactone combination improves
renal function more than does NAC alone. In the remnant kid-
ney model, early or late NAC administration has a protective
effect attributable to decreased plasma aldosterone and lower
levels of lipid peroxidation.
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Oxidative stress, resulting from the imbalance between
reactive oxygen species (ROS) and the antioxidant sys-
tem, contributes to the pathogenesis of different diseases.
Several studies have demonstrated that chronic renal fail-
ure is associated with oxidative stress [1, 2]. An antiox-
idant deficient diet increased the progression of renal
disease in animals with nephrectomy [3]. However, the
pathogenesis of oxidative stress in chronic renal failure
patients remains poorly defined [4]. Levels of malondi-
aldehyde (MDA), a product of lipid peroxidation, have
been shown to increase after 5/6 nephrectomy in rats.
The antioxidant N-acetylcysteine (NAC) is a source of
sulfhydryl groups in cells and, due to its interaction with
ROS, is a scavenger of free radicals [5]. It has been shown
that NAC administration improves endothelial function
while reducing inflammation, fibrosis, cartilage explants,
and acetaminophen liver metal toxicity [5]. In addition,
NAC decreases MDA levels in chronic hemodialysis pa-
tients [6] and ameliorates ischemic renal failure [7]. It has
also been used in the prevention of radiocontrast-induced
renal failure [8]. The effect of NAC on progressive renal
disease has not been previously evaluated.
Aldosterone contributes to renal injury in the remnant
kidney model [9]. In the heart, aldosterone-induced in-
flammation is also mediated by oxidative stress and at-
tenuated by NAC [10]. Aldosterone, partly via increased
oxidative stress, may mediate some of the angiotensin
II–induced vascular effects seen in hypertension [11].
Treatment with NAC reduces composite endpoints of car-
diovascular events in patients with end-stage renal failure
[12].
This study was carried out in order to determine the
effects of NAC on kidney function and aldosterone pro-
duction in the remnant kidney model.
METHODS
A total of 70 adult male Wistar rats (150 to 200 g)
were provided by the University of Sa˜o Paulo School of
Medicine for use in this study. All rats were anesthetized
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with 50 mg/kg of body weight of sodium pentobarbi-
tal, administered intraperitoneally, and were subjected
to either 5/6 nephrectomy, induced by right nephrectomy
and ligation of two branches of the renal artery, or la-
parotomy (sham operation). After recovering from the
anesthesia, the animals were returned to their original
cages and given free access to water and standard rat
chow (Nuvilab) (Curitiba, Brazil). Clearance studies
were performed, variously, on postoperative days 21, 60,
and 120. One day prior to each clearance study, rats were
housed in metabolic cages without food or water. The
Ethics in Research Committee of the University of Sa˜o
Paulo School of Medicine approved the study design.
Early NAC administration after 5/6 nephrectomy
or sham operation
In order to assess the effect of NAC administration
in the early stages of nephrectomy-induced renal failure,
animals were assigned to one of various groups, some
receiving NAC (600 mg/L in drinking water), initiated
on postoperative day 7, and some receiving no treat-
ment. The groups were defined as follows: sham/EV21
(sham operated and evaluated on postoperative day
21)(N = 6); nephrectomized/EV21 (nephrectomized and
evaluated on day 21) (N = 6); nephrectomized/EV60
(nephrectomized and evaluated on day 60) (N = 6);
nephrectomized/EV120 (nephrectomized and evaluated
on day 120) (N = 6); sham + NAC-IN7/EV21 (sham
operated, treated with NAC from day 7 and evaluated
on day 21) (N = 6); nephrectomized + NAC-IN7/EV21
(nephrectomized, treated with NAC from day 7 and eval-
uated on day 21) (N = 6); nephrectomized + NAC-
IN7/EV60 (nephrectomized, treated with NAC from day
7 and evaluated on day 60) (N = 6); and nephrectomized
+ NAC-IN7/EV120 (nephrectomized, treated with NAC
from day 7 and evaluated on day 120) (N = 6).
NAC administration in the later stages of renal failure
To evaluate the effect of NAC on end-stage renal fail-
ure, another group was created, composed of nephrec-
tomized rats receiving NAC (600 mg/L in drinking water)
initiated on postoperative day 60. These rats were evalu-
ated on postoperative day 120, and the group was desig-
nated nephrectomized + NAC-IN60/EV120 (N = 6).
Early administration of spironolactone
and the NAC-spironolactone combination
Two additional groups were created, both composed
of nephrectomized rats. The animals in one group re-
ceived spironolactone (1.5 g/kg of diet, initiated on post-
operative day 7) and were evaluated on postoperative
day 60. This group was designated nephrectomized +
spironolactone-IN7/EV60 (N = 8). Animals in the other
group, designated nephrectomized +spironolactone-
NAC-IN7/EV60 (N = 8) also received spironolactone
(in the same quantity), together with NAC (600 mg/L
in drinking water), both initiated on postoperative day 7,
and were also evaluated on postoperative day 60.
Urinary protein excretion and urinary levels
of thiobarbituric acid reactive substances (TBARS)
As previously mentioned, rats were housed in
metabolic cages without food or water before each clear-
ance study, and a 24-hour urine sample was collected in
order to determine urinary protein excretion and levels
of TBARS. Urinary protein excretion was determined
using the Sensiprot Kit (Labtest, Sa˜o Paulo, Brazil). Uri-
nary TBARS levels were assessed using the thiobarbituric
acid method, diluting a 0.2 mL urine sample in 0.8 mL
of distilled water, to which 1 mL of 17.5% trichloroacetic
acid was immediately added. Subsequently, 1 mL of 0.6%
thiobarbituric acid, pH 2, was added. The sample was
then placed in a boiling water bath for 15 minutes. Af-
ter the sample had cooled, 1 mL of 70% trichloroacetic
acid was added, and the mixture was allowed to incu-
bate for 20 minutes. The sample was then centrifuged for
15 minutes at 2000 rpm. The optical density of the super-
natant was read at 534 nm against a reagent blank using a
spectrophotometer. The concentration of lipid peroxida-
tion products was calculated as MDA equivalent using a
molar extinction coefficient for the MDA-thiobarbituric
acid complex of 1.56 × 105 mol−1/cm−1. Urinary levels of
TBARS were expressed as nmol/24 hours [3].
Clearance studies
Prior to the performance of the clearance studies, each
designated animal was anesthetized intraperitoneally
with sodium thiopental (50 mg/kg body weight). The
trachea was cannulated with a polyethylene (PE)-240
catheter, and spontaneous breathing was maintained. To
control mean arterial pressure and allow blood sampling,
the right carotid artery was catheterized with a PE-60
catheter. For infusion of inulin and fluids, the left jugu-
lar vein was cannulated with a PE-60 catheter. In order
to collect urine samples, a suprapubic incision was made,
and the urinary bladder was cannulated with a PE-240
catheter. Following the surgical procedure, a loading dose
of inulin (100 mg/kg body weight diluted in 0.9% saline)
was administered through the jugular vein. A constant
infusion of inulin (10 mg/kg body weight in 0.9% saline)
was then started and continued at 0.04 mL/min through-
out the experiment. A total of three urine samples were
collected at 30-minute intervals. Blood samples were ob-
tained at the beginning and end of the experiment. At
the clearance study end point, the kidneys were flushed
with saline and perfused with Dubosq-Brazil (modified
Bouin) fixative in situ at the measured arterial pressure.
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The renal tissue was then weighed, and two sections were
postfixed in buffered 10% formaldehyde solution. The
material was embedded in paraffin for later assessment
of glomerular and renal cortical interstitial injury. Hearts
and adrenal glands were also removed and weighed.
Blood and urine inulin were determined by the
anthrone method, and sodium and potassium con-
centrations were measured using a flame photometer
(model 143) (Instrumentation Laboratory, Lexington,
MA, USA). Glomerular filtration rate (GFR) and uri-
nary sodium/potassium (UNa/UK) ratio were calculated.
Serum aldosterone in blood samples obtained at the
end of the clearance study was determined by radioim-
munoassay (Coat-A-Count) DPC, Los Angeles, CA,
USA).
Histomorphometric analysis
Paraffin-embedded renal tissue was deparaffinized us-
ing standard techniques, and 2- to 3 m thick sections
were stained with periodic acid-Schiff (PAS) and Mas-
son trichrome technique. A single blinded observer per-
formed all histomorphometric measurements. The extent
of glomerular sclerosis was evaluated in four animals
on postnephrectomy day 60 and in six animals on post-
nephrectomy day 120. A score was attributed to each
glomerulus according to the extent of sclerotic injury: 0,
intact; 1, up to 10% damaged; 2, 11% to 20% damaged; 3,
21% to 30% damaged; 4, 31% to 40% damaged; 5, 41%
to 50% damaged; 6, 51% to 60% damaged; 7, 61% to
70% damaged; 8, 71% to 80% damaged; 9, 81% to 90%
damaged; and 10, 91% to 100% damaged. For each rat,
the glomerulosclerosis index (GSI) was calculated. The
GSI is a weighted average, multiplied by 100, of all indi-
vidual glomeruli thus obtained. At least 50 glomeruli per
rat were examined.
Fractional interstitial area
In kidneys obtained from nephrectomized/EV120 and
nephrectomized + NAC-IN7/EV120 group animals, the
fractional interstitial area of the renal cortex was deter-
mined by morphometry with a light camera connected to
an image analyzer (KS300) (Kontron, Munich, Germany)
[13]. Twenty 0.174 mm2 grid fields were evaluated in the
renal cortex of each kidney. Interstitial areas were first
manually encircled on a video screen and then deter-
mined by computerized morphometry.
Immunohistochemical analysis
Immunohistochemical analysis was performed for kid-
neys obtained from animals in the nephrectomized/
EV120 and nephrectomized + NAC-IN7/EV120 groups.
The primary antibodies used were a monoclonal anti-
rat endothelin-1 (ED-1) antibody to a cytoplasmic anti-
gen present in macrophages and monocytes (Serotec
Product Datasheet, Oxford, UK) and a monoclonal IgG
antibody to rat lymphocytes (CD3) (Harlan Sera-Lab,
Loughborough, England). The sections were incubated
for 1 hour with anti-ED-1 antibodies (macrophages)
(1:1000) or CD3 antibodies (lymphocytes) (1:1000). The
reaction product was detected with an avidin-biotin-
peroxidase complex (Vector Laboratories, Burlingame,
CA, USA). The color reaction was developed with 3,3′-
diaminobenzidine (DAB) (Sigma Chemical Company, St.
Louis, MO, USA), and the material was counterstained
(with methyl green for ED-1 or hematoxylin for ED-3),
then dehydrated and mounted. Nonspecific protein bind-
ing was blocked by incubation with 20% goat serum in
phosphate-buffered saline (PBS) for 20 minutes. Replac-
ing the primary antibody with mouse IgG, at an equiva-
lent concentration, created a negative control.
Infiltrating macrophages/monocytes and lymphocytes
in the renal cortex were counted in the tubulointersti-
tium and in the glomeruli using a 0.245 mm2 grid field or
30 glomeruli, respectively.
Statistical analysis
Data were analyzes using one-way analysis of vari-
ance (ANOVA) and Bonferroni’s post test using Graph-
Pad Prism (version 3.0) and Stata (version 8.0) statistical
software.
Data are mean ± SEM, a P value < 0.05 was consid-
ered to be significant at a two-tailed level. The ANOVA
and Bonferroni’s post test were used to analyze the GSI.
Analysis of the immunohistochemistry was performed us-
ing t test with Welch’s correction. Statistical significance
was established at P < 0.05.
RESULTS
Early NAC administration after 5/6 nephrectomy
or sham operation
There was a significant and progressive increase in
the body weight of all rats submitted to 5/6 nephrec-
tomy. However, nephrectomized + NAC-IN7/EV60 and
nephrectomized + NAC-IN7/EV120 rats presented sig-
nificantly higher mean body weight gain than did un-
treated nephrectomized rats (Table 1).
As illustrated in Table 1, NAC ingestion was sim-
ilar in all NAC-IN7–treated groups. Urinary protein
was significantly higher in nephrectomized rats than in
sham-operated rats. However, nephrectomized + NAC-
IN7/EV60 and nephrectomized + NAC-IN7/EV120 rats
presented lower levels of protein excretion than did un-
treated nephrectomized rats.
Urinary TBARS excretion was also lower in nephrec-
tomized + NAC-IN7 group rats than in untreated
nephrectomized rats. In nephrectomized + NAC-IN7/
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Table 1. Mean body weight gain, daily N-acetylcysteine (NAC) ingestion and 24-hour urinary excretion of protein and thiobarbituric acid
reactive substances (TBARS) on postoperative days 21, 60, and 120 in untreated rats and in rats receiving NAC initiated on postoperative day 7
NAC ingestion mg/100 g Urinary protein Urinary TBARS
Body weight body weight/day mg/24 hours nmol/24 hours
Sham/EV21 106 ± 10 — 4.74 ± 1.02 18.22 ± 2.41
Nephrectomized/EV21 133 ± 14 — 21.46 ± 2.71b 28.83 ± 3.22
Nephrectomized/EV60 141 ± 11 — 26.57 ± 2.99b 109.0 ± 17.95a
Nephrectomized/EV120 248 ± 20 — 207.5 ± 9.50a 254.0 ± 51.51a
Sham + NAC-IN7/EV21 98 ± 9 14.0 ± 0.5 3.41 ± 0.45 14.85 ± 1.64
Nephrectomized + NAC-IN7/EV21 146 ± 16 13.7 ± 0.6 14.78 ± 1.93 15.50 ± 0.89d
Nephrectomized + NAC-IN7/EV60 188 ± 13c 14.5 ± 0.3 15.62 ± 2.64 63.21 ± 6.32a,e
Nephrectomized + NAC-IN7/EV120 308 ± 16d 15.7 ± 0.8 158.6 ± 9.82a,d 91.69 ± 6.03a,e
Data expressed as mean ± SEM. Abbreviations are: BW, variation (increase) in body weight; sham, sham-operated; IN7, initiated (treatment) on postoperative
day 7; EV21, evaluated on postoperative day 21; EV60, evaluated on postoperative day 60; EV120, evaluated on postoperative day 120.
aP < 0.001; bP < 0.05, vs. sham-operated animals; cP < 0.01; dP < 0.005, eP < 0.02; comparison between treated and untreated groups by one-way analysis of
variance (ANOVA) and Bonferroni’s post test.
Table 2. Renal and systemic functional parameters on postoperative days 21, 60, and 120 in untreated rats and in rats receiving N-acetylcysteine
(NAC) initiated on postoperative day 7
Glomerular Uninary
Serum filtration rate Blood Fractional sodium/ Adrenal
aldosterone mL/min/100 g pressure excretion of potassium Heart weight
ng/dL body weight mm Hg potassium % ratio weight g mg
Sham/EV21 11 ± 2 0.83 ± 0.05 109 ± 3 28.4 ± 1.6 0.87 ± 0.03 0.85 ± 0.03 29 ± 0.25
Nephrectomized/EV21 288 ± 34a 0.25 ± 0.06a 138 ± 4a 34.0 ± 4.7 4.74 ± 1.61b 1.04 ± 0.03b 41 ± 2.70a
Nephrectomized/EV60 319 ± 50a 0.22 ± 0.06a 158 ± 3a 219.8 ± 46.9a 5.90 ± 2.03b 1.37 ± 0.06a 59 ± 0.84a
Nephrectomized/EV120 134 ± 12b 0.16 ± 0.03a 174 ± 5a 100.1 ± 22.1a 5.13 ± 0.69b 1.51 ± 0.07a 59 ± 2.02a
Sham + NAC-IN7/EV21 15 ± 2 0.93 ± 0.02 103 ± 1 24.0 ± 1.6 1.76 ± 0.32 0.81 ± 0.05 27 ± 0.88
Nephrectomized + NAC-IN7/EV21 54 ± 16a,c 0.48 ± 0.05a,f 134 ± 2a 28.3 ± 4.5 1.89 ± 0.62 1.04 ± 0.06b 45 ± 4.20a
Nephrectomized + NAC-IN7/EV60 125 ± 24a,c 0.47 ± 0.05a,e 154 ± 2a 46.7 ± 4.6a 1.63 ± 0.27 1.16 ± 0.04a,f 35 ± 2.10a,e
Nephrectomized + NAC-IN7/EV120 59 ± 2b,e 0.45 ± 0.04a,d 150 ± 7a,d 18.24 ± 2.2d 2.23 ± 0.72f 1.35 ± 0.05a 42 ± 1.7a,e
Data expressed as mean ± SEM. Abbreviations are: Sham, sham-operated; IN7, initiated (treatment) on postoperative day 7; EV21, evaluated on postoperative day
21; EV60, evaluated on postoperative day 60; EV120, evaluated on postoperative day 120.
aP < 0.001; bP < 0.05, vs. sham-operated animals; cP < 0.0001; dP < 0.005; eP < 0.01; fP < 0.05, comparison between treated and untreated groups by one-way
analysis of variance (ANOVA) and Bonferroni’s post test.
Table 3. Renal and systemic functional parameters on postoperative day 60 in nephrectomized rats receiving spironolactone alone or the
combination of spironolactone and N-acetylcysteine (NAC) initiated on postoperative day 7
Glomerular Urinary
Blood filtration rate sodium/ Heart Adrenal
pressure mL/min/100 g Proteinuria potassium Aldosterone TBARS weight weight
Group mm Hg body weight mg/24 hours ratio ng/dL nmol/24 hours g mg
Nephrectomized + spironolactone- 155 ± 3 0.28 ± 0.04 18 ± 1 0.90 ± 0.1 325 ± 77 118 ± 14 1.38 ± 0.03 57 ± 1.5
IN7/EV60
Nephrectomized + spironolactone + 136 ± 2a 0.59 ± 0.04a 14 ± 1b 0.66 ± 0.1 183 ± 20 81 ± 5b 1.31 ± 0.03 41 ± 1.4a
NAC-IN7/EV60
Data expressed as mean ± SEM. Abbreviations are: TBARS, thiobarbituric acid reactive substances; IN7, initiated (treatment) on postoperative day 7; EV60,
evaluated on postoperative day 60
aP < 0.0001 vs. nephrectomized + spironolactone only; bP < 0.03 vs. nephrectomized + spironolactone only, by unpaired t test.
EV21 rats, levels of TBARS were comparable to those
observed in sham-operated rats, whereas there was a sig-
nificant increase in this parameter in untreated nephrec-
tomized rats. In nephrectomized + NAC-IN7/EV60 and
nephrectomized + NAC-IN7/EV120 rats, respectively,
TBARS levels were approximately 40% and 60% lower
than in untreated nephrectomized rats (Table 1). These
data suggest that NAC reduces lipid peroxidation and at-
tenuates the renal injury responsible for the high protein
excretion in the 5/6 nephrectomy model.
Table 2 shows that inulin clearance (and therefore
GFR) fell progressively in nephrectomy rats in compari-
son to sham-operated rats (P < 0.001). Nevertheless, rats
in all nephrectomy + NAC-IN7 groups presented less
dramatic drops in GFR than did sham-operated rats, with
values almost 50% higher than those seen in untreated
nephrectomized rats.
Serum aldosterone increased significantly and pro-
gressively in nephrectomized rats compared with sham-
operated rats. However, rats in all nephrectomized +
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NAC-IN7 groups presented significantly lower serum lev-
els of this hormone, approximately five times lower in
nephrectomized + NAC-IN7/EV21 rats and 2.5 times
lower in nephrectomized + NAC-IN7/EV60 rats than
those seen in untreated nephrectomized rats. On postop-
erative day 120, all nephrectomized rats presented lower
serum aldosterone levels, although rats in the nephrec-
tomized + NAC-IN7 groups continued to present consid-
erably lower values than did untreated nephrectomized
rats (Table 2).
On postoperative days 60 and 120, fractional excretion
of potassium was significantly lower in nephrectomized +
NAC-IN7 group rats compared with untreated nephrec-
tomized rats. On postoperative day 120, the UNa/UK
ratio was significantly lower in all nephrectomized +
NAC-IN7 rats than in untreated nephrectomized rats
(Table 2).
Heart and adrenal weights also increased significantly
and progressively in nephrectomized rats (Table 2). By
postoperative day 21, the weights of these organs re-
mained unchanged. However, nephrectomized + NAC-
IN7/EV60 and nephrectomized + NAC-IN7/EV120 rats
presented significantly lower heart and adrenal weights,
indicating that NAC might have attenuated the hyper-
trophy of these organs during the progression of chronic
renal failure.
There were no differences in blood pressure be-
tween nephrectomized + NAC-IN7–treated and un-
treated nephrectomized rats evaluated at 21 and 60 days.
Nevertheless, a significant lower blood pressure was
observed in nephrectomized + NAC-IN7/EV120 rats
(Table 2).
As illustrated in Figure 1, the relative interstitial area
in nephrectomized/EV120 rats was 22.47 ± 3.66%, com-
pared with 10.17 ± 0.66% for nephrectomized + NAC-
IN7/EV120 rats (P < 0.03).
As can be seen in Figures 2 and 3, the number
of cells demonstrating ED-1 staining for macrophages/
monocytes was significantly lower in nephrectomized +
NAC-IN7/EV120 rats than in nephrectomized/EV120
rats, both in the glomeruli (1.46 ± 0.25 vs. 4.16 ± 0.70)
(P < 0.02) and in the tubulointerstitium (13.26 ± 1.80 vs.
34.59 ± 6.16) (P < 0.02).
The immunohistochemical analysis also showed sig-
nificantly lower numbers of infiltrating lymphocytes
in nephrectomized + NAC-IN7/EV120 rats than in
nephrectomized/EV120 rats, both in glomeruli (1.19 ±
0.26 vs. 2.10 ± 0.30) (P < 0.05) and in the tubulointersti-
tium (10.45 ± 0.61 vs. 27.12 ± 2.93) (P < 0.05) (Figs. 4
and 5).
NAC administration in the later stages of renal failure
In nephrectomized + NAC-IN60/EV120 rats, a pro-
tective effect similar to that seen in nephrectomized
30
20
10
0
Nx/EV120 Nx+NAC- 
IN7/EV120
P < 0.03*
*
%
Fig. 1. Fractional interstitial area in cortex of nephrectomized and eval-
uated on postoperative day 120 (Nx/EV120) and nephrectomized plus
N-acetylcysteine initiated treatment on day 7/evaluated on postopera-
tive day 120 (Nx + NAC-IN7/EV120) rats. Data are expressed as mean
± SEM (unpaired t test with Welch’s correction at P < 0.03).
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Fig. 2. Number of endothelin-1 (ED-1)–positive cells/mm2 in the
glomeruli and tubulointerstitium of nephrectomized/evaluated on
postoperative day 120 (Nx/EV120) and nephrectomized plus N-
acetylcysteine-initiated treatment on day 7/evaluated on postoperative
day 120 (Nx+NAC-IN7/EV120) rats. Data are expressed as mean ±
SEM (unpaired t test with Welch’s correction at P < 0.02).
+ NAC-IN7/EV120 rats was observed. Inulin clearance
was 0.51 ± 0.03 mL/min/100 g body weight; mean ar-
terial pressure was 159 ± 8 mm Hg; proteinuria was
134 ± 22 mg/day; urinary TBARS excretion was 127 ±
15 nmol/day; aldosterone 31 ± 4 ng/dL, UNa/UK was
1.3 ± 0.1, heart weight was 1.42 ± 0.07 g, and adrenal
weight was 43 ± 3 mg. Mean body weight gain in the
nephrectomized + NAC-IN60/EV120 group (336.7 ±
10.1 g) was comparable to that of the nephrectomized +
NAC-IN7/EV120 group. These results indicate that NAC
is protective even in end-stage renal failure.
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Fig. 3. Immunostaining for endothelin-1 (ED-1) (monocytes/
macrophages) in the renal cortices from nephrectomized/evaluated
on postoperative day 120 (Nx/EV120) rats (A) and nephrectomized
plus N-acetylcysteine initiated on day 7/evaluated on postoperative
day 120 (Nx+NAC-IN7/EV120) rats (B). Note that the number of
ED-1–positive cells is higher in (A).
As illustrated in Figure 6A, the GFR was higher
in nephrectomized + NAC-IN7/EV120 rats and in
nephrectomized + NAC-IN60/EV120 rats than in
nephrectomized/EV120 rats, whereas the GSI after
nephectomy was considerably lower in nephrectomized
+ NAC-IN7/EV120 rats and in nephrectomized + NAC-
IN60/EV120 rats than in nephrectomized/EV120 rats
(Fig. 6B)
The clearance data are from the surviving animals. In
nephrectomized/EV120 we started with nine rats, one of
which died on day 78, another one on day 98, and one
on day 103, as a result, we performed clearance studies
in six animals (33%). In the nephrectomized + NAC-
IN7/EV120 group, we started with eight rats. One died
on day 96 and another one on day 110, so six animals
were studied (25%). In the nephrectomized + NAC-
IN60/EV120 group, we started with seven animals and
only one died on day 97 (14.3%).
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Fig. 4. Number of CD3-positive cells/mm2 in the glomeruli and tubu-
lointerstitium of nephrectomized/evaluated on postoperative day 120
(Nx/EV120) and nephrectomized plus N-acetylcysteine initiated on day
7/evaluated on postoperative day 120 (Nx + NAC-IN7/EV120) rats.
Data are expressed as mean ± SEM (unpaired t test with Welch’s cor-
rection at P < 0.05).
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Fig. 5. Immunostaining for CD3 (T lymphocytes) in renal cortices from
nephrectomized/evaluated on postoperative day 120 (Nx/EV120) rats
(A) and nephrectomized plus N-acetylcysteine initiated on day 7/evalu-
ated on postoperative day 120 (Nx + NAC-IN7/EV120) rats (B). Note
that the number of CD3-positive cells is higher in (A).
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Fig. 6. (A) Inulin clearance and (B) glomerulosclerosis index in
nephrectomized/evaluated on postoperative day 120 (Nx/EV120),
nephrectomized plus N-acetylcysteine initiated on day 7/evaluated on
postoperative day 120 (Nx + NAC-IN7/EV120) and nephrectomized
plus N-acetylcysteine initiated on day 60/evaluated on postoperative
day 120 (Nx+NAC-IN60/EV120) groups. Data are expressed as mean
± SEM [analysis of variance (ANOVA) and Bonferroni’s post test, P <
0.05].
Spironolactone and the NAC-spironolactone
combination
Mean daily spironolactone ingestion was comparable
between the two groups (nephrectomized + spirono-
lactone-IN7/EV60 134 ± 7 mg/kg/day and nephrec-
tomized + spironolactone + NAC-IN7/EV60 126 ± 5 mg/
kg/day (not significant).
In the nephrectomized + spironolactone-IN7/EV60
group (Table 3), urinary protein excretion was lower
than in the nephrectomized/EV60 group (Table 1) (18 ±
1 mg/24 hours vs. 27 ± 2 mg/24 hours) (P < 0.001);
as was the UNa/UK ratio (0.90 ± 0.10 vs. 5.90 ± 2.0)
(P < 0.001). The inulin clearance was greater in nephrec-
tomized + spironolactone-IN7/EV60 (Table 3) than in
the nephrectomized/EV60 group (0.28 ± 0.04 vs. 0.21 ±
0.06 mL/min/100g body weight) (P < 0.05). The same was
observed in the case of arterial pressure (155 ± 3 vs. 158
± 3 mm Hg) (P < 0.05), whereas no differences were ob-
served in aldosterone, TBARS levels, heart, and adrenal
weight (Tables 1–3).
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Fig. 7. (A) Inulin clearance and (B) glomerulosclerosis index in
the nephrectomized/evaluated on postoperative day 60 (Nx/EV60),
nephrectomized plus spironolactone initiated on day 7/evaluated on
postoperative day 60 (Nx + SPI-IN7/EV60), nephrectomized plus
N-acetylcysteine initiated on day 7/evaluated on postoperative day 60
(Nx + NAC-IN7/EV60) and nephrectomized plus spironolactone plus
N-acetylcysteine initiated on day 7/evaluated on postoperative day 60
(Nx + SPI + NAC-IN7/EV60) groups. Data are expressed as mean ±
SEM [analysis of variance (ANOVA) and Bonferroni’s post test, P <
0.05].
The NAC-spironolactone combination resulted in
lower mean blood pressure than did spironolactone only
(nephrectomized + spironolactone + NAC-IN7/EV60
136 ± 2 mm Hg; nephrectomized + spironolactone-IN7/
EV60 155 ± 3 mm Hg) (P < 0.001). In addition, inulin
clearance in the nephrectomy + spironolactone + NAC-
IN7/EV60 group was 0.59 ± 0.04 mL/min/100 g body
weight, demonstrating an additive effect in comparison
to treatment with NAC alone (nephrectomized + NAC-
IN7/EV60 0.47 ± 0.05) (P < 0.001) (Fig. 7A, Table 3).
Mean GSI was significantly higher in the nephrec-
tomized/EV60 group than in any of the other groups
evaluated on postoperative day 60, the lowest GSI being
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Fig. 8. Correlation between proteinuria, corrected by inulin clearance
(UV prot/Cin), and the respective glomerulosclerosis index (GSI). Data
are from nephrectomized/evaluated on postoperative day 60, nephrec-
tomized plus spironolactone initiated on day 7/evaluated on postop-
erative day 60, nephrectomized plus N-acetylcysteine initiated on day
7/evaluated on postoperative day 60, nephrectomized plus spironolac-
tone plus N-acetylcysteine initiated on day 7/evaluated on postoperative
day 60, nephrectomized/evaluated on postoperative day 120, nephrec-
tomized plus N-acetylcysteine initiated on day 7/evaluated on postop-
erative day 120, and nephrectomized plus N-acetylcysteine initiated on
day 60/evaluated on postoperative day 120 groups.
observed in the nephrectomized + spironolactone +
NAC-IN7/EV60 group (Fig. 7B).
If we plot the rate of urinary excretion of protein/inulin
clearance with the respective glomerulosclerosis index of
animals, we obtain a positive correlation (Fig. 8) (r =
0.161, P < 0.008).
DISCUSSION
Our data demonstrate that TBARS urinary excretion
increases progressively in the remnant kidney model, in-
dicating that lipid peroxidation plays an important role in
the progression of chronic renal failure. Nath, Carott, and
Hostetter [14] showed that MDA per nephron increases
in a model of subtotal nephrectomy and is accompanied
by an increase in fractional and absolute urinary excre-
tion of MDA. A recent study showed that, in evaluating
patients with chronic kidney disease, the measurement
of oxidative damage markers (such as MDA) in urine is
a more sensitive method than the measurement of such
markers in plasma [15].
In the present study, we showed that NAC lowers lipid
peroxidation significantly and consistently for a period
of at least 120 days after subtotal nephrectomy. This was
accompanied by a significant protective effect on GFR
and renal inflammation, as well as by significant decreases
in aldosterone levels.
Subtotal (5/6) nephrectomy is widely used to create
experimental models of progressive nephropathy. Renal
inflammation is prominent in such models. Various meth-
ods of reducing renal injury in nephrectomized rats, such
as the administration of angiotensin-converting enzyme
(ACE) inhibitors, angiotensin II antagonists or immuno-
suppressive agents (such as mycophenolate mofetil),
have been employed [16–19]. All of these agents de-
creased proteinuria and reduced renal inflammation, as
evaluated by the GSI and tubulointerstitial injury scores.
However, significant protection of GFR, as determined
by inulin clearance, has not been reported.
The major new finding of the present study is that NAC
administration to 5/6 nephrectomized rats produced sig-
nificant protection against a decrease in GFR, maintain-
ing a mean inulin clearance of 0.45 mL/min (50% of
normal) that remained stable at 120 days after nephrec-
tomy. In contrast, GFR decreased progressively in the
untreated rats. Reductions in inflammation and in frac-
tional interstitial volume were observed in NAC-treated
rats at 120 days after nephrectomy. Although reductions
in proteinuria and blood pressure were also observed in
these rats, the protective effect that NAC had on GFR
was more impressive than the reduced proteinuria.
The data regarding GFR and glomerulosclerosis are
quite interesting. However, the antiproteinuric effect of
NAC at 120 days appears quite modest. Nevertheless,
if we correct the mean daily proteinuria by the respec-
tive mean inulin clearance, nephrectomized/EV120 rats
presented a four to five times greater protein excretion/
inulin clearance when compared to nephrectomized +
NAC-IN7/EV120 rats and nephrectomized + NAC-IN60/
EV120 rats. The same is true if we compare urinary ex-
cretion of protein/inulin clearance in nephrectomized/
EV60 rats to that observed in nephrectomized + NAC-
IN7/EV60 rats and nephrectomized + spironolactone +
NAC-IN7/EV60 rats.
In addition, a significant reduction in blood pressure
was not observed in NAC-treated rats until day 120. Sim-
ilar results have been obtained with administration of
the antioxidant vitamin E in a rat model of chronic ni-
tric oxide synthase inhibition [20] in which renal injury
was reduced, but there was no concomitant improve-
ment in hypertension. In spontaneously diabetic rats fed a
high-sodium diet, treatment with angiotensin II receptor
blockers has been shown to improve parameters without
affecting blood pressure [21].
Proteinuria and elevated blood pressure are predictors
of progressive kidney injury. Some studies suggest that
albumin can stimulate the production of proinflamma-
tory cytokines in proximal tubule cells by nuclear factor-
kappaB (NF-jB) activation [22, 23]. It is not known
whether the proinflammatory state and oxidative stress in
the kidney can be reduced without a significant reduction
in proteinuria and blood pressure.
A recent study was conducted involving patients with
chronic kidney disease who were being treated with
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an ACE inhibitor in combination with other antihyper-
tensive agents [15]. The authors submitted the patients
to additional angiotensin II blockade with losartan and
observed improvement in GFR with no effect on blood
pressure or proteinuria. The additional angiotensin II
blockade induced a 35% reduction in oxidized albumin
and a reduction in urinary excretion of monocyte chemo-
tactic protein-1, corresponding to the degree of renal in-
flammation. In another study of chronic kidney disease
patients, angiotensin II blockade also induced a 38% re-
duction in urinary excretion of the fibrogenic cytokine
transforming growth factor-b (TGF-b( [24]. Therefore,
as previously demonstrated, treatment with angiotensin
II receptor blockers improves oxidative stress parame-
ters in proteinuric patients with chronic kidney disease
without affecting blood pressure [25].
In our study, the combination of NAC and spirono-
lactone (nephrectomized spironolactone + NAC-IN7/
EV60 rats) was found to lower blood pressure and re-
duce oxidative stress, thereby conferring additive pro-
tection of GFR. This finding suggests a need for further
studies evaluating the effectiveness of treatment with
antioxidant-antihypertensives combinations in models of
chronic renal failure.
Administration of NAC has been shown to be protec-
tive in several types of organ injury. This is due to the fact
that NAC inhibits the activation of some protein kinases
and of NF-jB, which is an important transcription fac-
tor for a number of cytokine genes that may be activated
as a result of endothelial shear stress [5, 26, 27]. The ex-
pression of NF-jB–dependent genes may be important in
inducing endothelial cell death, as well as in generating a
local inflammatory reaction characterized by the release
of endothelial-derived cytokines [28].
Based on our data, we can conclude that NAC directly
regulates the proinflammatory effects of oxidative stress
in chronic kidney disease. These data may be significant
since current strategies for treating chronic kidney dis-
ease address the reduction of blood pressure and protein-
uria. Therefore, the addition of NAC to these treatment
regimens could be promising as a means of preventing the
oxidative stress complications of chronic kidney disease.
It is remarkable that aldosterone levels remained ele-
vated on day 120 after 5/6 nephrectomy, albeit to a lesser
degree than on day 60. A previous study carried out in our
laboratory showed that aldosterone levels were lower in
8-month-old rats than in younger rats [29]. In the present
study, the lower aldosterone levels seen at 120 days are
probably attributable to the aging of the animals and are
consistent with the lower fractional excretion of potas-
sium seen in these rats.
Rats treated with NAC presented noticeable decreases
in aldosterone levels as early as 21 days after nephrec-
tomy. Our data suggest that aldosterone makes only a
modest contribution to the induction of arterial hyper-
tension in the remnant kidney model since the marked
decrease in aldosterone levels in NAC-treated rats 21 and
60 days following nephrectomy was accompanied by only
a slight decrease in blood pressure.
Since high levels of aldosterone are necessary to main-
tain potassium balance in chronic renal failure, we can
hypothesize that the lower levels of aldosterone seen in
NAC-treated animals are a consequence of a lesser de-
gree of renal injury.
Nonhemodynamic effects of aldosterone may con-
tribute to glomerulosclerosis. Studies in vitro have shown
that production of type IV collagen increased in mesan-
gial cells incubated with aldosterone [30]. Transcripts for
the mineralocorticoid receptor have been detected in the
glomeruli, which may mediate the action of this hormone
at this site [31]. It is possible that the beneficial effect of
NAC on GFR and glomerulosclerosis is at least partly
mediated by aldosterone.
Sun et al [10] and Sarnak [32] demonstrated
aldosterone-induced inflammation in the rat heart. The
authors found this effect to be mediated by oxidative
stress and attenuated by NAC. In our study, cardiac hyper-
trophy, indirectly evaluated by determining heart weight,
increased progressively following nephrectomy. Heart
weights at 60 and 120 days after nephrectomy were sig-
nificantly higher in NAC-treated rats than in untreated
animals. It is possible that the lower levels of aldosterone
in NAC-treated rats are responsible for this effect.
CONCLUSION
Our data demonstrate that NAC attenuates drops in
GFR, as well as lowering proteinuria and blood pressure
in nephrectomized rats. This is accompanied by a signifi-
cant reduction in aldosterone levels. Our results indicate
that ROS play an important role in the progression of
chronic renal failure. It is evident that NAC has potential
utility in preventing glomerulosclerosis and loss of kidney
function in patients with chronic renal failure. The find-
ings that NAC attenuated GFR drop and lowered pro-
teinuria, even in end-stage chronic renal failure, and that
the combination of NAC and spironolactone improves re-
nal function more than does NAC alone have significant
clinical implications.
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